Real-world outcomes of niraparib treatment in patients with ovarian cancer : a multicenter non-interventional study in China
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Cancer communications (London, England) - 43(2023), 6 vom: 21. Juni, Seite 716-719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Jin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HMC2H89N35 |
|---|
| Anmerkungen: |
Date Completed 14.06.2023 Date Revised 25.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cac2.12418 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355447614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355447614 | ||
| 003 | DE-627 | ||
| 005 | 20231226064350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cac2.12418 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355447614 | ||
| 035 | |a (NLM)37040265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world outcomes of niraparib treatment in patients with ovarian cancer |b a multicenter non-interventional study in China |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.06.2023 | ||
| 500 | |a Date Revised 25.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a niraparib |2 NLM | |
| 650 | 7 | |a HMC2H89N35 |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 700 | 1 | |a Yang, Jianhua |e verfasserin |4 aut | |
| 700 | 1 | |a Shou, Huafeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xuedong |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huaying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ziting |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaojun |e verfasserin |4 aut | |
| 700 | 1 | |a Ju, Xingzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meiqin |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiaohua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer communications (London, England) |d 2018 |g 43(2023), 6 vom: 21. Juni, Seite 716-719 |w (DE-627)NLM28410809X |x 2523-3548 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:6 |g day:21 |g month:06 |g pages:716-719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cac2.12418 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 6 |b 21 |c 06 |h 716-719 | ||